Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 5NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1

Conditions

Waldenstrom Macroglobulinemia 3Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Lymphocytic, Chronic, B-Cell 2Burkitt Lymphoma 2Recurrence 1Lymphoma, Non-Hodgkin 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 30Vincristine 22Rituximab 19Etoposide 19Prednisone 18Filgrastim 16Doxorubicin 16Cytarabine 16Methotrexate 15Radiotherapy 14Peripheral Blood Stem Cell Transplantation 13merphos 11Leucovorin 11blinatumomab 10N,N-dicyclohexyl-isoborneol-10-sulfonamide 10Mercaptopurine 10Dexamethasone 10azathiopurine 9Specimen Handling 9Methylprednisolone 9Calcium Dobesilate 9Biopsy 9dexamethasone acetate 8dexamethasone 21-phosphate 8auricularum 8Cyclosporine 8prednylidene 7pegaspargase 7fludarabine phosphate 7deltacortene 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Burkitt Lymphoma × ibritumomab tiuxetan × Clear all
NCT00064246 2013-01-25

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

National Cancer Institute (NCI)

Phase 1/2 Completed
28 enrolled
Lymphoid

Burkitt Lymphoma, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse

NCT00036855 2013-01-17

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

National Cancer Institute (NCI)

Phase 1 Terminated
36 enrolled
LymphoidSarcoma

Burkitt Lymphoma, Recurrence, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡